A study to learn about the effects and safety of LIB-01 in healthy adults and participants with erectile dysfunction
Key facts
- Who runs it
- Dicot Pharma AB
- Where
- Sweden4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 115 people, planned
- Starts
- 30 Nov 2026
- Expected to end
- 16 Nov 2027
- Type of study
- Interventional
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- Healthy men will take part in Part 1 if they are aged between 18 and 65 years, weigh at least 50 kgs, are non-smokers within 3 months before joining this part, and are willing to use condoms from the start of treatment to 2 days after treatment or not engage in unprotected sex. Men with ED will take part in Part 2 if they are aged between 25 and 70 years, have a stable heterosexual relationship for at least 6 months, are willing to be sexually active at least once a week and use condoms from the start of treatment to 2 days after treatment or not engage in unprotected sex, and have a score below a certain level on a questionnaire that measures erectile functioning of men. For the full list of the inclusion criteria please refer to Protocol section 4.2
Who cannot take part
- Participants will be assessed to see if they have any conditions which might exclude them from participating, could interfere with the trial, or pose an unacceptable risk. Participants to whom any of the following applies will be excluded from the study: 1. Part 1: Multiple Dose Safety Cohort in Healthy Participants Exclusion Criteria 2. Part 2: Phase 2b Efficacy Study Exclusion Criteria For the full list of the exclusion criteria please refer to Protocol section 4.3
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Erectile dysfunction
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Part 1: To evaluate the safety and tolerability of repeated administrations of LIB-01 oral tablets up to 100 mg daily doses in healthy participants
Read full original descriptionShow less
Part 2: To evaluate the efficacy of repeated administrations of LIB-01 oral tablets in the treatment of ED for all active treatment groups pooled vs. placebo
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A phase 2b, randomized, double-blind, parallel, and placebo-controlled trial investigating efficacy and safety of LIB-01 in erectile dysfunction including an initial safety cohort in healthy adult participants
- Criteria questions
- Built from 2026-525955-98-00, who can take part
- Record updated
- 18 November 2026